<DOC>
	<DOCNO>NCT00717626</DOCNO>
	<brief_summary>The primary objective study test feasibility large-scale clinical trial once-daily prophylaxis . The secondary objective collect clinical efficacy outcome well plan large-scale study ; estimate effect size variability effect resource utilization once-daily prophylaxis allow u set sample size definitive trial .</brief_summary>
	<brief_title>Once-A-Day Prophylaxis Youth Young Adults With Severe Hemophilia A</brief_title>
	<detailed_description>Hemophilia important costly disorder ; left untreated , may serious consequence . The great impact hemophilia occur recurrent bleed joint . The consequence joint bleed include pain associate acute bleeding later chronic arthropathy . Half affect child severe hemophilia joint damage ; joint damage frequent increase bleeding . The prevention treatment bleed expensive therefore find cost-effective treatment high priority . Worldwide , two major treatment strategy use prevent arthropathy - demand therapy factor prophylaxis . The goal prophylaxis convert severe moderate phenotype provide circulate factor activity great 1 % . Patients great 1 % circulate factor VIII activity rarely spontaneous hemarthroses . Therefore , goal provide circulate factor level eliminate spontaneous hemarthroses . The term primary prophylaxis suggest use preventative factor VIII replacement early age . The term secondary prophylaxis use describe application prophylaxis later disease stage . In study , secondary prophylaxis use . Once-daily prophylaxis novel application hemophilia factor prophylaxis youth young adult . Before embark costly definitive trial feel necessary demonstrate subject willing enroll compliant therapy . Moreover , need establish estimate effect once-daily prophylaxis bleeding rate , quality life , joint damage progression order design definitive trial .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A ( &lt; 1 % factor VIII ) Age 12 24 year inclusive Male No current factor VIII inhibitor ( inhibitor define â‰¥ 0.6 Bethesda Units ) within past year Able participate home infusion program adequate peripheral venous access assess ny treat investigator Important comorbidities ( Acquired Immunodeficiency Syndrome symptomatic HIV infection , symptomatic hepatitis B C infection ) Other concomitant acquire congenital bleeding disorder ( e.g . von Willebrand 's Disease ) Receiving factor VIII replacement central venous catheter</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Hemophilia</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Youth</keyword>
	<keyword>Young Adults</keyword>
	<keyword>Feasibility</keyword>
</DOC>